Dual adeno-associated virus (AAV) technology was developed in 2000 to double the packaging capacity of the AAV vector. The proof of principle has been demonstrated in various mouse models. Yet, pivotal evidence is lacking in large animal models of human diseases. Here we report expression of a 7-kb canine ΔH2–R15 mini-dystrophin gene using a pair of dual AAV vectors in the canine model of Duchenne muscular dystrophy (DMD). The ΔH2–R15 minigene is by far the most potent synthetic dystrophin gene engineered for DMD gene therapy. We packaged minigene dual vectors in Y731F tyrosine-modified AAV-9 and delivered to the extensor carpi ulnaris muscle of a 12-month-old affected dog at the dose of 2 × 1013 viral genome particles/vector/muscle. Widespread mini-dystrophin expression was observed 2 months after gene transfer. The missing dystrophin-associated glycoprotein complex was restored. Treatment also reduced muscle degeneration and fibrosis and improved myofiber size distribution. Importantly, dual AAV therapy greatly protected the muscle from eccentric contraction-induced force loss. Our data provide the first clear evidence that dual AAV therapy can be translated to a diseased large mammal. Further development of dual AAV technology may lead to effective therapies for DMD and many other diseases in human patients.
Get full access to this article
View all access options for this article.
References
1.
KunkelLM. 2004 William Allan award address. cloning of the DMD gene. Am J Hum Genet, 2005; 76:205–214.
2.
KoenigM, HoffmanEP, BertelsonCJ, et al.Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 1987; 50:509–517.
3.
LaiY, YueY, DuanD. Evidence for the failure of adeno-associated virus serotype 5 to package a viral genome > or = 8.2 kb. Mol Ther, 2010; 18:75–79.
4.
DongJY, FanPD, FrizzellRA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther, 1996; 7:2101–2112.
5.
DongB, NakaiH, XiaoW. Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther, 2010; 18:87–92.
6.
FaninM, FredaMP, VitielloL, et al.Duchenne phenotype with in-frame deletion removing major portion of dystrophin rod: threshold effect for deletion size?. Muscle Nerve, 1996; 19:1154–1160.
7.
EnglandSB, NicholsonLV, Johnson MA et, al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature, 1990; 343:180–182.
8.
HarperSQ, HauserMA, DelloRussoC, et al.Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med, 2002; 8:253–261.
9.
LaiY, ThomasGD, YueY, et al.Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest, 2009; 119:624–635.
10.
LaiY, ZhaoJ, YueY, et al.Alpha2 and alpha3 helices of dystrophin R16 and R17 frame a microdomain in the alpha1 helix of dystrophin R17 for neuronal NOS binding. Proc Natl Acad Sci U S A, 2013; 110:525–530.
DuanD, YueY, YanZ, et al.A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat Med, 2000; 6:595–598.
15.
YanZ, ZhangY, DuanD, et al.Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A, 2000; 97:6716–6721.
16.
DuanD, YueY, EngelhardtJF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther, 2001; 4:383–391.
17.
GhoshA, YueY, LaiY, et al.A hybrid vector system expands aden-associated viral vector packaging capacity in a transgene independent manner. Mol Ther, 2008; 16:124–130.
GhoshA, DuanD. Expending adeno-associated viral vector capacity: a tale of two vectors. Biotechnol Genet Eng Rev, 2007; 24:165–177.
20.
ChamberlainK, RiyadJM, WeberT. Expressing transgenes that exceed the packaging capacity of adeno-associated virus capsids. Hum Gene Ther Methods, 2016; 27:1–12.
21.
HirschML, WolfSJ, SamulskiRJ. Delivering transgenic DNA exceeding the carrying capacity of AAV vectors. Methods Mol Biol, 2016; 1382:21–39.
22.
LaiY, YueY, LiuM, et al.Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol, 2005; 23:1435–1439.
23.
GhoshA, YueY, ShinJ-H, et al.Systemic trans-splicing AAV delivery efficiently transduces the heart of adult mdx mouse, a model for Duchenne muscular dystrophy. Hum Gene Ther, 2009; 20:1319–1328.
24.
GhoshA, YueY, LongC, et al.Efficient whole-body transduction with trans-splicing adeno-associated viral vectors. Mol Ther, 2007; 15:750–755.
25.
OdomGL, GregorevicP, AllenJM, et al.Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol Ther, 2011; 19:36–45.
26.
SmithBF, YueY, WoodsPR, et al.An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the Corgi breed. Lab Invest, 2011; 91:216–231.
27.
FineDM, ShinJH, YueY, et al.Age-matched comparison reveals early electrocardiography and echocardiography changes in dystrophin-deficient dogs. Neuromuscul Disord, 2011; 21:453–461.
28.
SharpNJ, KornegayJN, Van CampSD, et al.An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics, 1992; 13:115–121.
29.
Petrs-SilvaH, DinculescuA, LiQ, et al.High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther, 2009; 17:463–471.
30.
ShinJH, YueY, DuanD. Recombinant adeno-associated viral vector production and purification. Methods Mol Biol, 2012; 798:267–284.
31.
ShinJH, PanX, HakimCH, et al.Microdystrophin ameliorates muscular dystrophy in the canine model of Duchenne muscular dystrophy. Mol Ther, 2013; 21:750–757.
32.
HakimCH, YueY, ShinJH, et al.Systemic gene transfer reveals distinctive muscle transduction profile of tyrosine mutant AAV-1, -6, and -9 in neonatal dogs. Mol Ther Methods Clin Dev, 2014; 1:14002.
33.
YueY, PanX, HakimCH, et al.Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum Mol Genet, 2015; 24:5880–5890.
34.
ShinJH, YueY, SrivastavaA, et al.A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs. Hum Gene Ther, 2012; 23:202–209.
35.
YangHT, ShinJH, HakimCH, et al.Dystrophin deficiency compromises force production of the extensor carpi ulnaris muscle in the canine model of Duchenne muscular dystrophy. PLoS One, 2012; 7:e44438.
36.
KodippiliK, VinceL, ShinJH, et al.Characterization of 65 epitope-specific dystrophin monoclonal antibodies in canine and murine models of Duchenne muscular dystrophy by immunostaining and western blot. PLoS One, 2014; 9:e88280.
37.
WasalaNB, LaiY, ShinJH, et al.Genomic removal of a therapeutic mini-dystrophin gene from adult mice elicits a Duchenne muscular dystrophy-like phenotype. Hum Mol Genet, 2016; 25:2633–2644.
38.
BhosleRC, MicheleDE, CampbellKP, et al.Interactions of intermediate filament protein synemin with dystrophin and utrophin. Biochem Biophys Res Commun, 2006; 346:768–777.
39.
ReynoldsJG, McCalmonSA, DonagheyJA, et al.Deregulated protein kinase A signaling and myospryn expression in muscular dystrophy. J Biol Chem, 2008; 283:8070–8074.
40.
AyalonG, DavisJQ, ScotlandPB, et al.An ankyrin-based mechanism for functional organization of dystrophin and dystroglycan. Cell, 2008; 135:1189–1200.
41.
RezniczekGA, KoniecznyP, NikolicB, et al.Plectin 1f scaffolding at the sarcolemma of dystrophic (mdx) muscle fibers through multiple interactions with beta-dystroglycan. J Cell Biol, 2007; 176:965–977.
42.
Ishikawa-SakuraiM, YoshidaM, ImamuraM, et al.ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to beta-dystroglycan. Hum Mol Genet, 2004; 13:693–702.
43.
HuangX, PoyF, ZhangR, et al.Structure of a WW domain containing fragment of dystrophin in complex with beta-dystroglycan. Nat Struct Biol, 2000; 7:634–638.
44.
NeweySE, BensonMA, PontingCP, et al.Alternative splicing of dystrobrevin regulates the stoichiometry of syntrophin binding to the dystrophin protein complex. Curr Biol, 2000; 10:1295–1298.
45.
Sadoulet-PuccioHM, RajalaM, KunkelLM. Dystrobrevin and dystrophin: an interaction through coiled-coil motifs. Proc Natl Acad Sci U S A, 1997; 94:12413–12418.
46.
UrsittiJA, LeePC, ResneckWG, et al.Cloning and characterization of cytokeratins 8 and 19 in adult rat striated muscle. Interaction with the dystrophin glycoprotein complex. J Biol Chem, 2004; 279:41830–41838.
47.
PrinsKW, HumstonJL, MehtaA, et al.Dystrophin is a microtubule-associated protein. J Cell Biol, 2009; 186:363–369.
48.
BelantoJJ, MaderTL, EckhoffMD, et al.Microtubule binding distinguishes dystrophin from utrophin. Proc Natl Acad Sci U S A, 2014; 111:5723–5728.
49.
BanuelosS, SarasteM, Djinovic CarugoK. Structural comparisons of calponin homology domains: implications for actin binding. Structure, 1998; 6:1419–1431.
50.
NorwoodFL, Sutherland-SmithAJ, KeepNH, et al.The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy. Structure, 2000; 8:481–491.
51.
NigroG, PolitanoL, NigroV, et al.Mutation of dystrophin gene and cardiomyopathy. Neuromuscul Disord, 1994; 4:371–379.
52.
LostalW, KodippiliK, YueY, et al.Full-length dystrophin reconstitution with adeno-associated viral vectors. Hum Gene Ther, 2014; 25:552–562.
53.
WangZ, KuhrCS, AllenJM, et al.Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther, 2007; 15:1160–1166.
54.
FlotteTR. Size does matter: overcoming the adeno-associated virus packaging limit. Respir Res, 2000; 1:16–18.
55.
SamulskiRJ. Expanding the AAV package. Nat Biotechnol, 2000; 18:497–498.
56.
LostalW, BartoliM, BourgN, et al.Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet, 2010; 19:1897–1907.
57.
ColellaP, TrapaniI, CesiG, et al.Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors. Gene Ther, 2014; 21:450–456.
58.
SondergaardPC, GriffinDA, PozsgaiER, et al.AAV.Dysferlin overlap vectors restore function in dysferlinopathy animal models. Ann Clin Transl Neurol, 2015; 2:256–270.
59.
MendellJR, KisselJT, AmatoAA, et al.Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med, 1995; 333:832–838.
60.
WagnerKR, FleckensteinJL, AmatoAA, et al.A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol, 2008; 63:561–571.
McGreevyJW, HakimCH, McIntoshMA, et al.Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech, 2015; 8:195–213.
63.
DuanD. Duchenne muscular dystrophy gene therapy: lost in translation?. Res Rep Biol, 2011; 2:31–42.
64.
DuanD. Duchenne muscular dystrophy gene therapy in the canine model. Hum Gene Ther Clin Dev, 2015; 26:57–69.
65.
BodorM, McDonaldCM. Why short stature is beneficial in Duchenne muscular dystrophy. Muscle Nerve, 2013; 48:336–342.
66.
ValentineBA, CooperBJ, de LahuntaA, et al.Canine X-linked muscular dystrophy–an animal model of Duchenne muscular dystrophy: clinical studies. J Neurol Sci, 1988; 88:69–81.
67.
KooT, MalerbaA, AthanasopoulosT, et al.Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of alpha1-syntrophin and alpha-dystrobrevin in skeletal muscles of mdx mice. Hum Gene Ther, 2011; 22:1379–1388.
68.
MendellJR, SahenkZ, MalikV, et al.A phase I/IIa follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther, 2015; 23:192–201.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
